United States Pharmaceutical Contract Manufacturing Organization (CMO) Market 2021 Business Outlook - Catalent Inc., Recipharm AB, Jubilant Life Sciences Ltd, Thermo Fisher Scientific

The “United States Pharmaceutical Contract Manufacturing Organization (CMO) Market” report 2021-2026 is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from industry experts and professionals. The study is a detailed document on key aspects of the markets including trends, segmentation, growth prospects, opportunities, challenges, and competitive analysis.

The US pharmaceutical contract manufacturing organization (CMO) market is expected to reach a CAGR of 5 % during the forecast period of 2021 to 2026.

The report is updated with the impact of the currently ongoing COVID-19 pandemic. The pandemic has dynamically affected key market segments and changed the growth pattern and demands in the Pharmaceutical Contract Manufacturing Organization (CMO) market. The report covers an in-depth analysis of these changes and provides an accurate estimate of the market growth forecast after the impact of the pandemic.

Click the link to get a free Sample Copy of the Report: (Flat 25%)

https://www.marketinsightsreports.com/reports/05202906882/united-states-pharmaceutical-contract-manufacturing-organization-cmo-market-growth-trends-covid-19-impact-and-forecasts-2021-2026/inquiry?Mode=28    

The research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Top Companies in the United States Pharmaceutical Contract Manufacturing Organization (CMO) Market: Catalent Inc., Recipharm AB, Jubilant Life Sciences Ltd, Thermo Fisher Scientific Inc. (Patheon Inc.), Boehringer Ingelheim Group, Pfizer CentreSource (Pfizer Inc.), Aenova Group, AbbVie Contract Manufacturing, Baxter Biopharma Solutions (Baxter International Inc.), Lonza Group AG, Siegfried AG, and Other.

Industry News and Update:

- February 2020 - Alchem Laboratories Corporation announced an expansion of its screening and clinical trial manufacturing capabilities. The expansion was made through construction of Building 3, a 12,000 square foot multi-use facility dedicated to high-throughput screening, biologic and drug product manufacturing clean-room areas, and analytical support.

- December 2019 - Thermo Fisher Scientific Inc. introduced its new USD 90 million viral vector CDMO site in Lexington, Massachusetts. The 50,000-square-foot facility will support the development, testing, and manufacture of viral vectors, which are critical to advancing new life-saving gene and cell therapies.

Key Market Trends:

Increasing Demand of API to Witness Significant Market Growth

- The demand for API manufacturing witnessed a sustained rise in the past few years, and it is expected to continue growing steadily. As of August 2019, 28% of the manufacturing facilities making APIs for the US markets are based in the United States.

- Further, the increasing prevalence of infectious diseases, cardiovascular conditions, and other chronic and genetic disorders are driving the market of API. For instance, The Alzheimer's Association stated that an estimated 5.8 million Americans aging 65 and older have Alzheimer's dementia in 2020. 80% are age 75 or older, and this number is predicted to reach approx 14 million, worsening the situation over the forecast period. Also, by 2050, a new case of the disease is expected to develop every 33 seconds. This significantly demands more API facility prevailing high stock.

- Furthermore, according to Hemp Business Journal, till 2022, the estimated sales of hemp-based CBD products in the United States is USD 522 million (human) and USD 125 million (pet/animal). The Wall Street investment firm estimated that in 2018, Americans spent about USD 2 billion on CBD API mostly for treating anxiety, pain, or sleep issues. By 2025, Wall Street predicts that the market value will rise to USD 16 billion. With the increasing rate of chronic pain, anxiety, inflammation, and insomnia in the United States people, this significantly supports the market growth.

- Moreover, in context to CBD, in April 2019, Emerald Health Pharmaceuticals and Lonza announced an agreement for the large expansion in the manufacturing of a new synthetic derivative of CBD for the treatment of multiple sclerosis (MS) and systemic scleroderma. Under the agreement, Lonza Pharma & Biotech focuses on synthesizing the API / drug substance (VCE-004.8) and develop the drug product (EHP-101) as liquid-filled capsules.

Ask for TOC and Report Description:

https://www.marketinsightsreports.com/reports/05202906882/united-states-pharmaceutical-contract-manufacturing-organization-cmo-market-growth-trends-covid-19-impact-and-forecasts-2021-2026?Mode=28    

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a United States and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The United States Pharmaceutical Contract Manufacturing Organization (CMO) Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Purchase Full report@:

https://www.marketinsightsreports.com/report/purchase/05202906882?mode=su?Mode=28    

The research includes historic data from 2015 to 2021 and forecasts until 2026 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Market Insights Reports
4893, Pepper drive, Harrisburg ,NC 28075,United States

Irfan Tamboli (Head of Sales)
Market Insights Reports
Phone: + 1704 266 3234 | Mob: +91-750-707-8687
sales@marketinsightsreports.com
irfan@marketinsightsreports.com

We also offer customization on reports based on specific client requirement:
1- Free country level analysis for any 5 countries of your choice.
2- Free competitive analysis of any 5 key market players.
3- Free 40 analyst hours to cover any other data points

This release was published on openPR.